ATE450499T1 - Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten - Google Patents

Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten

Info

Publication number
ATE450499T1
ATE450499T1 AT03791043T AT03791043T ATE450499T1 AT E450499 T1 ATE450499 T1 AT E450499T1 AT 03791043 T AT03791043 T AT 03791043T AT 03791043 T AT03791043 T AT 03791043T AT E450499 T1 ATE450499 T1 AT E450499T1
Authority
AT
Austria
Prior art keywords
sup
sub
independently
compounds
treatment
Prior art date
Application number
AT03791043T
Other languages
English (en)
Inventor
C J Springer
Ion Niculescu-Duvaz
D M Niculescu-Duvaz
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE450499T1 publication Critical patent/ATE450499T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03791043T 2002-09-02 2003-09-01 Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten ATE450499T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220319.8A GB0220319D0 (en) 2002-09-02 2002-09-02 Enzyme activated self-immolative nitrogen mustard drugs
PCT/GB2003/003736 WO2004020400A1 (en) 2002-09-02 2003-09-01 Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs

Publications (1)

Publication Number Publication Date
ATE450499T1 true ATE450499T1 (de) 2009-12-15

Family

ID=9943326

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791043T ATE450499T1 (de) 2002-09-02 2003-09-01 Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten

Country Status (8)

Country Link
US (1) US7235585B2 (de)
EP (1) EP1534670B1 (de)
AT (1) ATE450499T1 (de)
AU (1) AU2003259382A1 (de)
CA (1) CA2496470A1 (de)
DE (1) DE60330356D1 (de)
GB (1) GB0220319D0 (de)
WO (1) WO2004020400A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ, インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (de) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Festen formen von isochinolinonen
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (de) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und verwendungen davon
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (de) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Kombinationstherapie
JP7458997B2 (ja) 2018-05-29 2024-04-01 ブリストル-マイヤーズ スクイブ カンパニー プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820850D0 (en) 1988-09-05 1988-10-05 Cancer Res Campaign Tech Improvements relating to pro-drugs
GB8920011D0 (en) 1989-09-05 1989-10-18 Mann J New route of synthesis for tertiary butyl esters
GB9308957D0 (en) 1993-04-30 1993-06-16 Cancer Res Campaign Tech Novel produgs
CA2167153A1 (en) 1993-07-15 1995-01-26 Caroline Joy Springer Prodrugs of protein tyrosine kinase inhibitors
GB9315494D0 (en) 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis

Also Published As

Publication number Publication date
WO2004020400A1 (en) 2004-03-11
AU2003259382A1 (en) 2004-03-19
US20060069154A1 (en) 2006-03-30
CA2496470A1 (en) 2004-03-11
GB0220319D0 (en) 2002-10-09
EP1534670A1 (de) 2005-06-01
US7235585B2 (en) 2007-06-26
EP1534670B1 (de) 2009-12-02
DE60330356D1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
DE60330356D1 (en) Stickstoff-lost-derivaten
ATE495155T1 (de) Heterocyclische inhibitoren von mek
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
BR0306292A (pt) Composto de éster e uso medicinal do mesmo
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
TW200612936A (en) Indole derivatives
ATE484514T1 (de) Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
DE60235299D1 (de) 4-aryl substituierte chinole und analoga als therapeutische wirkstoffe
WO2004066952A3 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
IL151167A0 (en) Pyrrolopyridazine derivatives and pharmaceutical compositions containing the same
EP1806136A4 (de) Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie
WO2005035500A3 (en) Therapeutic agents useful for treating pain
IL169577A0 (en) Oligosaccharide derivatives and pharmaceutical compostions containing the same
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties